Valuation: Simulations Plus

Market Cap 372M 333M 307M 278M 519M 35.33B 529M 3.66B 1.47B 18.59B 1.4B 1.37B 58.62B P/E 2024
74x
P/E 2025 -4.4x
Enterprise Value 340M 305M 280M 254M 475M 32.32B 484M 3.34B 1.34B 17B 1.28B 1.25B 53.62B EV / Sales 2024
10.1x
EV / Sales 2025 3.2x
Free-Float
99.98%
Yield 2024
0.66%
Yield 2025 -
Current month+0.38%
1 month+0.38%
3 months+1.09%
6 months+30.56%
Current year+1.48%
1 month 18.49
Extreme 18.49
18.5
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
51.22
5 years 11.09
Extreme 11.09
67.59
10 years 8.3
Extreme 8.3
90.92
Manager TitleAgeSince
Chief Executive Officer 67 2018-06-25
Director of Finance/CFO 63 2020-11-30
Chief Tech/Sci/R&D Officer - -
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Issuer sale

Chairman

-23,547 0.1169%
10/6/26 Issuer sale

Chief Financial Officer

-109,600 0.5440%
10/6/26 Issuer sale

Founder

-3,207,131 15.9190%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+7.81%-45.40% 374M
-1.72%+3.44%+25.31%+60.56% 258B
-2.00%+0.75%+7.99%+25.46% 163B
-3.73%-4.48%-18.49%+67.13% 150B
-1.66%-8.12%-58.26%-16.12% 60.84B
-2.57%+3.30%+10.22%+47.55% 53.03B
0.00%+2.46%-11.97%-6.29% 53.31B
-3.47%+1.04%+21.98%+72.85% 49.3B
+0.84%-3.12%+9.80%+64.47% 50.67B
-3.61%+1.99%+34.94%+95.49% 45.46B
Average -1.79%-0.26%+2.93%+36.57% 88.38B
Weighted average by Cap. -2.10%+0.15%+5.19%+47.75%

Financials

2024 2025
Net sales 70.01M 62.7M 57.68M 52.26M 97.69M 6.65B 99.52M 688M 276M 3.5B 263M 257M 11.03B 79.18M 70.91M 65.23M 59.1M 110M 7.52B 113M 778M 312M 3.95B 297M 291M 12.47B
Net income 9.95M 8.91M 8.2M 7.43M 13.89M 945M 14.15M 97.79M 39.26M 497M 37.36M 36.56M 1.57B -64.72M -57.96M -53.32M -48.31M -90.3M -6.15B -91.99M -636M -255M -3.23B -243M -238M -10.19B
Net Debt -19.25M -17.24M -15.86M -14.37M -26.86M -1.83B -27.36M -189M -75.91M -961M -72.24M -70.7M -3.03B -31.74M -28.42M -26.15M -23.69M -44.28M -3.01B -45.11M -312M -125M -1.59B -119M -117M -5B
Projected Income Statement - Annual - Simulations Plus
Logo Simulations Plus
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Simulations Plus